Shamina Rangwala

Shamina joined Flagship’s Pioneering Medicines in 2024 as Vice President of Project Leadership. Shamina is responsible for leading multiple obesity and metabolism partnerships between Pioneering Medicines, external pharma partners, and Flagship platform companies.

Before joining Flagship, Shamina led business development activities to build the early Internal Medicine portfolio at Pfizer where she identified novel therapies and technologies for research collaborations, in-licensing, acquisition, and venture investment in cardiovascular and metabolic diseases. Previously, Shamina led Johnson & Johnson and Novo Nordisk efforts to identify clinical candidates for obesity and metabolic disease. She started her industry career at NIBR in Cardiovascular and Metabolism, focused on skeletal muscle health and mitochondrial function.

Shamina holds a Ph.D. in Pharmacology from the Ohio State University and completed her post-doctoral fellowship at the University of Pennsylvania, where her research focused on body weight regulation and insulin resistance. She has authored more than 25 manuscripts and patents, contributing to journals such as Cell, Science and Nature.